BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Scarpignato C, Pelosini I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy. 2005;51 Suppl 1:36-66. [PMID: 15855748 DOI: 10.1159/000081990] [Cited by in Crossref: 132] [Cited by in F6Publishing: 128] [Article Influence: 7.8] [Reference Citation Analysis]
Number Citing Articles
1 Shayto RH, Abou Mrad R, Sharara AI. Use of rifaximin in gastrointestinal and liver diseases. World J Gastroenterol 2016; 22(29): 6638-6651 [PMID: 27547007 DOI: 10.3748/wjg.v22.i29.6638] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
2 Orrego-Lagarón N, Martínez-Huélamo M, Vallverdú-Queralt A, Lamuela-Raventos RM, Escribano-Ferrer E. High gastrointestinal permeability and local metabolism of naringenin: influence of antibiotic treatment on absorption and metabolism. Br J Nutr 2015;114:169-80. [PMID: 26083965 DOI: 10.1017/S0007114515001671] [Cited by in Crossref: 28] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
3 Jiang ZD, DuPont HL, La Rocco M, Garey KW. In vitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, Texas. J Clin Pathol. 2010;63:355-358. [PMID: 20354207 DOI: 10.1136/jcp.2009.071688] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
4 Dogan H, Ocal H, Safak T, Kilinc MA, Risvanli A. Dose related inhibitor effect of enrofloxacin on in vitro feline spontaneous myometrial contractility. Animal Reproduction Science 2022. [DOI: 10.1016/j.anireprosci.2022.106972] [Reference Citation Analysis]
5 Laube R, Paramsothy S, Leong RW. Use of medications during pregnancy and breastfeeding for Crohn's disease and ulcerative colitis. Expert Opin Drug Saf 2021;20:275-92. [PMID: 33412078 DOI: 10.1080/14740338.2021.1873948] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Zhuang X, Tian Z, Luo M, Xiong L. Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome. BMC Gastroenterol 2020;20:187. [PMID: 32532214 DOI: 10.1186/s12876-020-01336-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
7 Schmulson M, Bielsa MV, Carmona-sánchez R, Hernández A, López-colombo A, Vidal YL, Peláez-luna M, Remes-troche JM, Tamayo JL, Valdovinos MA. Microbiota, gastrointestinal infections, low-grade inflammation, and antibiotic therapy in irritable bowel syndrome (IBS): an evidence-based review. Revista de Gastroenterología de México (English Edition) 2014;79:96-134. [DOI: 10.1016/j.rgmxen.2014.01.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
8 Bujnowski K, Synoradzki L, Darłak RC, Zevaco TA, Dinjus E. Semi-synthetic zwitterionic rifamycins: a promising class of antibiotics; survey of their chemistry and biological activities. RSC Adv 2016;6:114758-72. [DOI: 10.1039/c6ra22880a] [Cited by in Crossref: 11] [Article Influence: 1.8] [Reference Citation Analysis]
9 Scarpignato C, Hunt RH. Nonsteroidal antiinflammatory drug-related injury to the gastrointestinal tract: clinical picture, pathogenesis, and prevention. Gastroenterol Clin North Am. 2010;39:433-464. [PMID: 20951911 DOI: 10.1016/j.gtc.2010.08.010] [Cited by in Crossref: 148] [Cited by in F6Publishing: 132] [Article Influence: 13.5] [Reference Citation Analysis]
10 Miftahussurur M, Aftab H, Shrestha PK, Sharma RP, Subsomwong P, Waskito LA, Doohan D, Fauzia KA, Yamaoka Y. Effective therapeutic regimens in two South Asian countries with high resistance to major Helicobacter pylori antibiotics. Antimicrob Resist Infect Control 2019;8:40. [PMID: 30815255 DOI: 10.1186/s13756-019-0482-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
11 Di Mario F, Cavallaro LG, Scarpignato C. ‘Rescue’ therapies for the management of Helicobacter pylori infection. Dig Dis. 2006;24:113-130. [PMID: 16699270 DOI: 10.1159/000090315] [Cited by in Crossref: 37] [Cited by in F6Publishing: 42] [Article Influence: 2.3] [Reference Citation Analysis]
12 Abraham B, Quigley EMM. Antibiotics and probiotics in inflammatory bowel disease: when to use them? Frontline Gastroenterol 2020;11:62-9. [PMID: 31885842 DOI: 10.1136/flgastro-2018-101057] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
13 McHale C, Keating E, O'Donovan H, Slattery E. D-lactic acidosis presenting as metabolic encephalopathy in a patient with short bowel syndrome. BMJ Case Rep 2021;14:e241102. [PMID: 33986009 DOI: 10.1136/bcr-2020-241102] [Reference Citation Analysis]
14 Kimer N, Pedersen JS, Busk TM, Gluud LL, Hobolth L, Krag A, Møller S, Bendtsen F; Copenhagen Rifaximin (CoRif) Study Group. Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double-blind, placebo-controlled trial. Hepatology 2017;65:592-603. [PMID: 27775818 DOI: 10.1002/hep.28898] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 8.6] [Reference Citation Analysis]
15 Kimer N, Pedersen JS, Tavenier J, Christensen JE, Busk TM, Hobolth L, Krag A, Al-Soud WA, Mortensen MS, Sørensen SJ, Møller S, Bendtsen F; members of the CoRif study group. Rifaximin has minor effects on bacterial composition, inflammation, and bacterial translocation in cirrhosis: A randomized trial. J Gastroenterol Hepatol 2018;33:307-14. [PMID: 28671712 DOI: 10.1111/jgh.13852] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
16 Blandizzi C, Viscomi GC, Scarpignato C. Impact of crystal polymorphism on the systemic bioavailability of rifaximin, an antibiotic acting locally in the gastrointestinal tract, in healthy volunteers. Drug Des Devel Ther 2015;9:1-11. [PMID: 25565769 DOI: 10.2147/DDDT.S72572] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
17 Robins GW, Wellington K. Rifaximin: a review of its use in the management of traveller’s diarrhoea. Drugs. 2005;65:1697-1713. [PMID: 16060706 DOI: 10.2165/00003495-200565120-00011] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
18 Husebye E. The pathogenesis of gastrointestinal bacterial overgrowth. Chemotherapy. 2005;51 Suppl 1:1-22. [PMID: 15855746 DOI: 10.1159/000081988] [Cited by in Crossref: 90] [Cited by in F6Publishing: 89] [Article Influence: 5.3] [Reference Citation Analysis]
19 Kessoku T, Kobayashi T, Imajo K, Tanaka K, Yamamoto A, Takahashi K, Kasai Y, Ozaki A, Iwaki M, Nogami A, Honda Y, Ogawa Y, Kato S, Higurashi T, Hosono K, Yoneda M, Okamoto T, Usuda H, Wada K, Kobayashi N, Saito S, Nakajima A. Endotoxins and Non-Alcoholic Fatty Liver Disease. Front Endocrinol (Lausanne) 2021;12:770986. [PMID: 34777261 DOI: 10.3389/fendo.2021.770986] [Reference Citation Analysis]
20 Pistiki A, Galani I, Pyleris E, Barbatzas C, Pimentel M, Giamarellos-Bourboulis EJ. In vitro activity of rifaximin against isolates from patients with small intestinal bacterial overgrowth. Int J Antimicrob Agents 2014;43:236-41. [PMID: 24461710 DOI: 10.1016/j.ijantimicag.2013.12.008] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
21 Mu H, Bai H, Sun F, Liu Y, Lu C, Qiu Y, Chen P, Yang Y, Kong L, Duan J. Pathogen-targeting glycovesicles as a therapy for salmonellosis. Nat Commun 2019;10:4039. [PMID: 31492864 DOI: 10.1038/s41467-019-12066-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
22 Lanas A, Scarpignato C. Microbial flora in NSAID-induced intestinal damage: a role for antibiotics? Digestion. 2006;73 Suppl 1:136-150. [PMID: 16498262 DOI: 10.1159/000089789] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 3.5] [Reference Citation Analysis]
23 Guslandi M. Probiotics in diverticular disease: not ready for prime time? Expert Rev Gastroenterol Hepatol 2013;7:585-6. [PMID: 24070148 DOI: 10.1586/17474124.2013.832491] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
24 Gatta L, Scarpignato C. Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther. 2017;45:604-616. [PMID: 28078798 DOI: 10.1111/apt.13928] [Cited by in Crossref: 78] [Cited by in F6Publishing: 63] [Article Influence: 15.6] [Reference Citation Analysis]
25 Calvet X. Helicobacter pylori infection: treatment options. Digestion. 2006;73 Suppl 1:119-128. [PMID: 16498260 DOI: 10.1159/000089787] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
26 Scarpignato C, Pelosini I. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. Digestion. 2006;73 Suppl 1:13-27. [PMID: 16498249 DOI: 10.1159/000089776] [Cited by in Crossref: 73] [Cited by in F6Publishing: 68] [Article Influence: 4.6] [Reference Citation Analysis]
27 Chang C, Huang CH, Tseng HJ, Yang FC, Chien RN. Real-World Experience of the One-Year Efficacy of Rifaximin Add-On to Lactulose Is Superior to Lactulose Alone in Patients with Cirrhosis Complicated with Recurrent Hepatic Encephalopathy in Taiwan. J Pers Med 2021;11:478. [PMID: 34071787 DOI: 10.3390/jpm11060478] [Reference Citation Analysis]
28 Piccinno M, Rizzo A, Maselli M, Derosa M, Sciorsci R. Modulatory effect of three antibiotics on uterus bovine contractility in vitro and likely therapeutic approaches in reproduction. Theriogenology 2014;82:1287-95. [DOI: 10.1016/j.theriogenology.2014.08.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
29 Soriano MM, Johnson S. Treatment of Clostridium difficile Infections. Infectious Disease Clinics of North America 2015;29:93-108. [DOI: 10.1016/j.idc.2014.11.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
30 Theis KR, Florova V, Romero R, Borisov AB, Winters AD, Galaz J, Gomez-Lopez N. Sneathia: an emerging pathogen in female reproductive disease and adverse perinatal outcomes. Crit Rev Microbiol 2021;47:517-42. [PMID: 33823747 DOI: 10.1080/1040841X.2021.1905606] [Reference Citation Analysis]
31 Karanje RV, Bhavsar YV, Jahagirdar KH, Bhise KS. Formulation and development of extended-release micro particulate drug delivery system of solubilized rifaximin. AAPS PharmSciTech 2013;14:639-48. [PMID: 23516110 DOI: 10.1208/s12249-013-9949-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
32 Parenti F, Lancini G. Rifamycins. Antibiotic and Chemotherapy. Elsevier; 2010. pp. 326-33. [DOI: 10.1016/b978-0-7020-4064-1.00027-0] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
33 Schmulson M, Bielsa MV, Carmona-Sánchez R, Hernández A, López-Colombo A, López Vidal Y, Peláez-Luna M, Remes-Troche JM, Tamayo JL, Valdovinos MA. Microbiota, gastrointestinal infections, low-grade inflammation, and antibiotic therapy in irritable bowel syndrome: an evidence-based review. Rev Gastroenterol Mex. 2014;79:96-134. [PMID: 24857420 DOI: 10.1016/j.rgmx.2014.01.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
34 Surowiec D, Kuyumjian AG, Wynd MA, Cicogna CE. Past, present, and future therapies for Clostridium difficile-associated disease. Ann Pharmacother 2006;40:2155-63. [PMID: 17148650 DOI: 10.1345/aph.1H332] [Cited by in Crossref: 37] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
35 Zullo A, Hassan C, Ridola L, Lorenzetti R, Campo SM, Riggio O. Rifaximin therapy and hepatic encephalopathy: Pros and cons. World J Gastrointest Pharmacol Ther 2012; 3(4): 62-67 [PMID: 22966484 DOI: 10.4292/wjgpt.v3.i4.62] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
36 Iorio N, Malik Z, Schey R. Profile of rifaximin and its potential in the treatment of irritable bowel syndrome. Clin Exp Gastroenterol 2015;8:159-67. [PMID: 26089696 DOI: 10.2147/CEG.S67231] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
37 Bandzar S, Gupta S, Platt MO. Crohn’s disease: a review of treatment options and current research. Cell Immunol. 2013;286:45-52. [PMID: 24321565 DOI: 10.1016/j.cellimm.2013.11.003] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 4.6] [Reference Citation Analysis]
38 Gasbarrini A, Gasbarrini G, Pelosini I, Scarpignato C. Eradication of Helicobacter pylori: are rifaximin-based regimens effective? Digestion. 2006;73 Suppl 1:129-135. [PMID: 16498261 DOI: 10.1159/000089788] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
39 Festi D, Vestito A, Mazzella G, Roda E, Colecchia A. Management of hepatic encephalopathy: focus on antibiotic therapy. Digestion. 2006;73 Suppl 1:94-101. [PMID: 16498257 DOI: 10.1159/000089784] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
40 Huang E, Esrailian E, Spiegel BM. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy - a decision analysis. Aliment Pharmacol Ther. 2007;26:1147-1161. [PMID: 17894657 DOI: 10.1111/j.1365-2036.2007.03464.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 3.5] [Reference Citation Analysis]
41 Gasbarrini A, Lauritano EC, Nista EC, Candelli M, Gabrielli M, Santoro M, Zocco MA, Cazzato A, Finizio R, Ojetti V. Rifaximin-based regimens for eradication of Helicobacter pylori: a pilot study. Dig Dis. 2006;24:195-200. [PMID: 16699278 DOI: 10.1159/000090330] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
42 Pons MJ, Mensa L, Gascón J, Ruiz J. Fitness and Molecular Mechanisms of Resistance to Rifaximin in In Vitro Selected Escherichia coli Mutants. Microbial Drug Resistance 2012;18:376-9. [DOI: 10.1089/mdr.2011.0010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
43 Ponziani FR, Zocco MA, D’Aversa F, Pompili M, Gasbarrini A. Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation. World J Gastroenterol 2017; 23(25): 4491-4499 [PMID: 28740337 DOI: 10.3748/wjg.v23.i25.4491] [Cited by in CrossRef: 57] [Cited by in F6Publishing: 44] [Article Influence: 11.4] [Reference Citation Analysis]
44 Cruciani F, Brigidi P, Calanni F, Lauro V, Tacchi R, Donders G, Peters K, Guaschino S, Vitali B. Efficacy of rifaximin vaginal tablets in treatment of bacterial vaginosis: a molecular characterization of the vaginal microbiota. Antimicrob Agents Chemother 2012;56:4062-70. [PMID: 22585228 DOI: 10.1128/AAC.00061-12] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
45 Ojetti V, Lauritano EC, Barbaro F, Migneco A, Ainora ME, Fontana L, Gabrielli M, Gasbarrini A. Rifaximin pharmacology and clinical implications. Expert Opin Drug Metab Toxicol. 2009;5:675-682. [PMID: 19442033 DOI: 10.1517/17425250902973695] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
46 Sohal A, Green V, Sandhu S, Roytman M. Identifying areas of improvement in nursing knowledge regarding hepatic encephalopathy management. J Community Hosp Intern Med Perspect 2021;11:722-6. [PMID: 34567473 DOI: 10.1080/20009666.2021.1954784] [Reference Citation Analysis]
47 Prantera C, Lochs H, Campieri M, Scribano ML, Sturniolo GC, Castiglione F, Cottone M. Antibiotic treatment of Crohn’s disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther. 2006;23:1117-1125. [PMID: 16611272 DOI: 10.1111/j.1365-2036.2006.02879.x] [Cited by in Crossref: 116] [Cited by in F6Publishing: 109] [Article Influence: 7.3] [Reference Citation Analysis]
48 Ferro D, Baratta F, Pastori D, Cocomello N, Colantoni A, Angelico F, Del Ben M. New Insights into the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Gut-Derived Lipopolysaccharides and Oxidative Stress. Nutrients 2020;12:E2762. [PMID: 32927776 DOI: 10.3390/nu12092762] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
49 Chang JY, Kim SE, Kim TH, Woo SY, Ryu MS, Joo YH, Lee KE, Lee J, Lee KH, Moon CM, Jung HK, Shim KN, Jung SA. Emergence of rifampin-resistant staphylococci after rifaximin administration in cirrhotic patients. PLoS One 2017;12:e0186120. [PMID: 28982166 DOI: 10.1371/journal.pone.0186120] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
50 Tandon P, Delisle A, Topal JE, Garcia-Tsao G. High prevalence of antibiotic-resistant bacterial infections among patients with cirrhosis at a US liver center. Clin Gastroenterol Hepatol. 2012;10:1291-1298. [PMID: 22902776 DOI: 10.1016/j.cgh.2012.08.017] [Cited by in Crossref: 105] [Cited by in F6Publishing: 96] [Article Influence: 10.5] [Reference Citation Analysis]
51 Montagnese S, Russo FP, Amodio P, Burra P, Gasbarrini A, Loguercio C, Marchesini G, Merli M, Ponziani FR, Riggio O, Scarpignato C. Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). Dig Liver Dis. 2019;51:190-205. [PMID: 30606696 DOI: 10.1016/j.dld.2018.11.035] [Cited by in Crossref: 30] [Cited by in F6Publishing: 18] [Article Influence: 7.5] [Reference Citation Analysis]
52 Ma X, Shah YM, Guo GL, Wang T, Krausz KW, Idle JR, Gonzalez FJ. Rifaximin is a gut-specific human pregnane X receptor activator. J Pharmacol Exp Ther. 2007;322:391-398. [PMID: 17442842 DOI: 10.1124/jpet.107.121913] [Cited by in Crossref: 79] [Cited by in F6Publishing: 78] [Article Influence: 5.3] [Reference Citation Analysis]
53 Nishida S, Hamada K, Nishino N, Fukushima D, Koyanagi R, Horikawa Y, Shiwa Y, Saitoh S. Efficacy of long-term rifaximin treatment for hepatic encephalopathy in the Japanese. World J Hepatol 2019; 11(6): 531-541 [PMID: 31293721 DOI: 10.4254/wjh.v11.i6.531] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
54 Lopetuso LR, Napoli M, Rizzatti G, Gasbarrini A. The intriguing role of Rifaximin in gut barrier chronic inflammation and in the treatment of Crohn’s disease. Expert Opinion on Investigational Drugs 2018;27:543-51. [DOI: 10.1080/13543784.2018.1483333] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
55 Bajaj JS, Barbara G, DuPont HL, Mearin F, Gasbarrini A, Tack J. New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases. Dig Liver Dis 2018;50:741-9. [PMID: 29807873 DOI: 10.1016/j.dld.2018.04.020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
56 Jodlowski TZ, Oehler R, Kam LW, Melnychuk I. Emerging Therapies in the Treatment of Clostridium difficile–Associated Disease. Ann Pharmacother 2006;40:2164-9. [DOI: 10.1345/aph.1h340] [Cited by in Crossref: 22] [Cited by in F6Publishing: 5] [Article Influence: 3.7] [Reference Citation Analysis]
57 Di Mario F, Miraglia C, Cambiè G, Violi A, Nouvenne A, Franceschi M, Brandimarte G, Elisei W, Picchio M, Tursi A. Long-term efficacy of rifaximin to manage the symptomatic uncomplicated diverticular disease of the colon. J Investig Med 2019;67:767-70. [PMID: 30593541 DOI: 10.1136/jim-2018-000901] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
58 Yang J, Lee H, Low K, Chatterjee S, Pimentel M. Rifaximin versus Other Antibiotics in the Primary Treatment and Retreatment of Bacterial Overgrowth in IBS. Dig Dis Sci 2008;53:169-74. [DOI: 10.1007/s10620-007-9839-8] [Cited by in Crossref: 84] [Cited by in F6Publishing: 74] [Article Influence: 5.6] [Reference Citation Analysis]
59 Colucci R, Pellegrini C, Fornai M, Tirotta E, Antonioli L, Renzulli C, Ghelardi E, Piccoli E, Gentile D, Benvenuti L, Natale G, Fulceri F, Palazón-Riquelme P, López-Castejón G, Blandizzi C, Scarpignato C. Pathophysiology of NSAID-Associated Intestinal Lesions in the Rat: Luminal Bacteria and Mucosal Inflammation as Targets for Prevention. Front Pharmacol 2018;9:1340. [PMID: 30555323 DOI: 10.3389/fphar.2018.01340] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
60 Mearin F. Pharmacological treatment of the irritable bowel syndrome and other functional bowel disorders. Digestion. 2006;73 Suppl 1:28-37. [PMID: 16498250 DOI: 10.1159/000089777] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
61 Pelosini I, Scarpignato C. Rifaximin, a Peculiar Rifamycin Derivative: Established and Potential Clinical Use Outside the Gastrointestinal Tract. Chemotherapy 2005;51:122-30. [DOI: 10.1159/000081999] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
62 Maconi G. Diagnosis of symptomatic uncomplicated diverticular disease and the role of Rifaximin in management. Acta Biomed 2017;88:25-32. [PMID: 28467330 DOI: 10.23750/abm.v88i1.6360] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
63 Lee HJ, Choi JK, Ryu HS, Choi CH, Kang EH, Park KS, Min YW, Hong KS. Therapeutic Modulation of Gut Microbiota in Functional Bowel Disorders. J Neurogastroenterol Motil 2017;23:9-19. [PMID: 28049862 DOI: 10.5056/jnm16124] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
64 Robertsen HL, Musiol-Kroll EM. Actinomycete-Derived Polyketides as a Source of Antibiotics and Lead Structures for the Development of New Antimicrobial Drugs. Antibiotics (Basel) 2019;8:E157. [PMID: 31547063 DOI: 10.3390/antibiotics8040157] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
65 Laterza L, Ianiro G, Scoleri I, Landi R, Bruno G, Scaldaferri F, Gaetani E, Campanale M, Gasbarrini A. Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome. Expert Opin Pharmacother. 2015;16:607-615. [PMID: 25641072 DOI: 10.1517/14656566.2015.1007951] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
66 Scarpignato C, Dolak W, Lanas A, Matzneller P, Renzulli C, Grimaldi M, Zeitlinger M, Bjarnason I. Rifaximin Reduces the Number and Severity of Intestinal Lesions Associated With Use of Nonsteroidal Anti-Inflammatory Drugs in Humans. Gastroenterology 2017;152:980-982.e3. [PMID: 28007576 DOI: 10.1053/j.gastro.2016.12.007] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
67 Sidhu GS, Go A, Attar BM, Mutneja HR, Arora S, Patel SA. Rifaximin versus norfloxacin for prevention of spontaneous bacterial peritonitis: a systematic review. BMJ Open Gastroenterol. 2017;4:e000154. [PMID: 28944070 DOI: 10.1136/bmjgast-2017-000154] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
68 Song M, Ang TL. Second and third line treatment options for Helicobacter pylori eradication. World J Gastroenterol 2014; 20(6): 1517-1528 [PMID: 24587627 DOI: 10.3748/wjg.v20.i6.1517] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
69 Schmidt AC, Leroux J. Treatments of trimethylaminuria: where we are and where we might be heading. Drug Discovery Today 2020;25:1710-7. [DOI: 10.1016/j.drudis.2020.06.026] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
70 Garcovich M, Zocco MA, Roccarina D, Ponziani FR, Gasbarrini A. Prevention and treatment of hepatic encephalopathy: Focusing on gut microbiota. World J Gastroenterol 2012; 18(46): 6693-6700 [PMID: 23239905 DOI: 10.3748/wjg.v18.i46.6693] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 37] [Article Influence: 3.8] [Reference Citation Analysis]
71 Sartor RB. Review article: the potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases. Aliment Pharmacol Ther. 2016;43 Suppl 1:27-36. [PMID: 26618923 DOI: 10.1111/apt.13436] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
72 Remes Troche J. Reflexiones sobre la resistencia a antibióticos y qué hacer al respecto. Revista de Gastroenterología de México 2016;81:1-2. [DOI: 10.1016/j.rgmx.2016.01.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
73 Fornai M, Antonioli L, Pellegrini C, Colucci R, Sacco D, Tirotta E, Natale G, Bartalucci A, Flaibani M, Renzulli C, Ghelardi E, Blandizzi C, Scarpignato C. Small bowel protection against NSAID-injury in rats: Effect of rifaximin, a poorly absorbed, GI targeted, antibiotic. Pharmacol Res 2016;104:186-96. [PMID: 26747402 DOI: 10.1016/j.phrs.2015.12.031] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
74 Cremonini F, Lembo A. Rifaximin for the treatment of irritable bowel syndrome. Expert Opin Pharmacother. 2012;13:433-440. [PMID: 22251066 DOI: 10.1517/14656566.2012.651458] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
75 Graziano T, Amoruso A, Nicola S, Deidda F, Allesina S, Pane M, Piffanelli P, Strozzi F, Mogna L, Del Piano M. The Possible Innovative Use of Bifidobacterium longum W11 in Association With Rifaximin: A New Horizon for Combined Approach? Journal of Clinical Gastroenterology 2016;50:S153-6. [DOI: 10.1097/mcg.0000000000000683] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.2] [Reference Citation Analysis]
76 Rosette C, Agan FJ, Rosette N, Moro L, Mazzetti A, Hassan C, Gerloni M. Rifamycin SV exhibits strong anti-inflammatory in vitro activity through pregnane X receptor stimulation and NFκB inhibition. Drug Metabolism and Pharmacokinetics 2019;34:172-80. [DOI: 10.1016/j.dmpk.2019.01.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
77 Blandizzi C, Viscomi GC, Marzo A, Scarpignato C. Is generic rifaximin still a poorly absorbed antibiotic? A comparison of branded and generic formulations in healthy volunteers. Pharmacol Res. 2014;85:39-44. [PMID: 24836868 DOI: 10.1016/j.phrs.2014.05.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
78 Gough EK, Moodie EE, Prendergast AJ, Johnson SM, Humphrey JH, Stoltzfus RJ, Walker AS, Trehan I, Gibb DM, Goto R, Tahan S, de Morais MB, Manges AR. The impact of antibiotics on growth in children in low and middle income countries: systematic review and meta-analysis of randomised controlled trials. BMJ 2014;348:g2267. [PMID: 24735883 DOI: 10.1136/bmj.g2267] [Cited by in Crossref: 79] [Cited by in F6Publishing: 74] [Article Influence: 9.9] [Reference Citation Analysis]
79 Caraceni P, Vargas V, Solà E, Alessandria C, de Wit K, Trebicka J, Angeli P, Mookerjee RP, Durand F, Pose E, Krag A, Bajaj JS, Beuers U, Ginès P; Liverhope Consortium. The Use of Rifaximin in Patients With Cirrhosis. Hepatology 2021;74:1660-73. [PMID: 33421158 DOI: 10.1002/hep.31708] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 20.0] [Reference Citation Analysis]
80 Zaccherini G, Tufoni M, Bernardi M, Caraceni P. Prevention of Cirrhosis Complications: Looking for Potential Disease Modifying Agents. J Clin Med 2021;10:4590. [PMID: 34640608 DOI: 10.3390/jcm10194590] [Reference Citation Analysis]
81 Corazza GR, Di Stefano M, Scarpignato C. Treatment of functional bowel disorders: is there room for antibiotics? Digestion 2006;73 Suppl 1:38-46. [PMID: 16498251 DOI: 10.1159/000089778] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
82 Bajaj JS. Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis. Aliment Pharmacol Ther. 2016;43 Suppl 1:11-26. [PMID: 26618922 DOI: 10.1111/apt.13435] [Cited by in Crossref: 53] [Cited by in F6Publishing: 42] [Article Influence: 8.8] [Reference Citation Analysis]
83 Guiles J, Critchley I, Sun X. New agents for Clostridium difficile-associated disease. Expert Opin Investig Drugs 2008;17:1671-83. [PMID: 18922104 DOI: 10.1517/13543784.17.11.1671] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
84 Neff GW, Kemmer N, Zacharias VC, Kaiser T, Duncan C, McHenry R, Jonas M, Novick D, Williamson C, Hess K. Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy. Transplant Proc. 2006;38:3552-3555. [PMID: 17175328 DOI: 10.1016/j.transproceed.2006.10.107] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 2.7] [Reference Citation Analysis]
85 Phongsamran PV, Kim JW, Cupo Abbott J, Rosenblatt A. Pharmacotherapy for Hepatic Encephalopathy: . Drugs 2010;70:1131-48. [DOI: 10.2165/10898630-000000000-00000] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 4.3] [Reference Citation Analysis]
86 Bruzzese E, Pesce M, Sarnelli G, Guarino A. Pharmacokinetic drug evaluation of rifaximin for treatment of diarrhea-predominant irritable bowel syndrome. Expert Opin Drug Metab Toxicol 2018;14:753-60. [PMID: 29897844 DOI: 10.1080/17425255.2018.1488964] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
87 Keser N, Is M, Ceman D, Somay A. Locally Used Antibiotics for Spinal Infection Prophylaxis and Their Effects on Epidural Fibrosis: an Experimental Laminectomy Study in Rats Using Rifamycin and Gentamycin. Inflammation 2019;42:714-20. [PMID: 30413905 DOI: 10.1007/s10753-018-0929-x] [Reference Citation Analysis]
88 Tursi A, Scarpignato C, Strate LL, Lanas A, Kruis W, Lahat A, Danese S. Colonic diverticular disease. Nat Rev Dis Primers 2020;6:20. [PMID: 32218442 DOI: 10.1038/s41572-020-0153-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
89 Guslandi M. Rifaximin in the treatment of inflammatory bowel disease. World J Gastroenterol 2011; 17(42): 4643-4646 [PMID: 22180705 DOI: 10.3748/wjg.v17.i42.4643] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 31] [Article Influence: 2.6] [Reference Citation Analysis]
90 Jahraus CD, Brandt S, Bettenhausen D. Recognizing and treating a new entity on the quality-of-life front: small intestinal bacterial overgrowth. Community Oncology 2007;4:625-9. [DOI: 10.1016/s1548-5315(11)70044-4] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
91 Uchida Y, Tsuji S, Uemura H, Kouyama JI, Naiki K, Sugawara K, Nakao M, Inao M, Nakayama N, Imai Y, Tomiya T, Mochida S. Furosemide as a factor to deteriorate therapeutic efficacy of rifaximin in patients with decompensated cirrhosis. Hepatol Res 2020;50:1264-74. [PMID: 32833292 DOI: 10.1111/hepr.13564] [Reference Citation Analysis]
92 Suzuki H, Sezaki H, Suzuki F, Kasuya K, Sano T, Fujiyama S, Kawamura Y, Hosaka T, Akuta N, Saitoh S, Kobayashi M, Arase Y, Ikeda K, Suzuki Y, Kumada H. Real‐world effects of long‐term rifaximin treatment for Japanese patients with hepatic encephalopathy. Hepatol Res 2019;49:1406-13. [DOI: 10.1111/hepr.13415] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
93 Mencarelli A, Migliorati M, Barbanti M, Cipriani S, Palladino G, Distrutti E, Renga B, Fiorucci S. Pregnane-X-receptor mediates the anti-inflammatory activities of rifaximin on detoxification pathways in intestinal epithelial cells. Biochemical Pharmacology 2010;80:1700-7. [DOI: 10.1016/j.bcp.2010.08.022] [Cited by in Crossref: 62] [Cited by in F6Publishing: 61] [Article Influence: 5.2] [Reference Citation Analysis]
94 Kimer N, Krag A, Bendtsen F, Møller S, Gluud LL; Cochrane Hepato-Biliary Group. Rifaximin for people with hepatic encephalopathy. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd011585] [Cited by in Crossref: 4] [Article Influence: 0.6] [Reference Citation Analysis]
95 Sopeña F, Lanas A. Management of colonic diverticular disease with poorly absorbed antibiotics and other therapies. Therap Adv Gastroenterol 2011;4:365-74. [PMID: 22043229 DOI: 10.1177/1756283X11412820] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
96 Mantry PS, Munsaf S. Rifaximin for the treatment of hepatic encephalopathy. Transplant Proc. 2010;42:4543-4547. [PMID: 21168733 DOI: 10.1016/j.transproceed.2010.09.173] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
97 Weber D, Oefner PJ, Dettmer K, Hiergeist A, Koestler J, Gessner A, Weber M, Stämmler F, Hahn J, Wolff D, Herr W, Holler E. Rifaximin preserves intestinal microbiota balance in patients undergoing allogeneic stem cell transplantation. Bone Marrow Transplant 2016;51:1087-92. [PMID: 26999466 DOI: 10.1038/bmt.2016.66] [Cited by in Crossref: 61] [Cited by in F6Publishing: 59] [Article Influence: 10.2] [Reference Citation Analysis]
98 Ponziani FR, Gerardi V, Pecere S, D’Aversa F, Lopetuso L, Zocco MA, Pompili M, Gasbarrini A. Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications. World J Gastroenterol 2015; 21(43): 12322-12333 [PMID: 26604640 DOI: 10.3748/wjg.v21.i43.12322] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 34] [Article Influence: 5.3] [Reference Citation Analysis]
99 Qi X, Yang M, Stenberg J, Dey R, Fogwe L, Alam MS, Kimchi ET, Staveley-O'Carroll KF, Li G. Gut microbiota mediated molecular events and therapy in liver diseases. World J Gastroenterol 2020; 26(48): 7603-7618 [PMID: 33505139 DOI: 10.3748/wjg.v26.i48.7603] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
100 Miller MA, Blanchette R, Spigaglia P, Barbanti F, Mastrantonio P. Divergent rifamycin susceptibilities of Clostridium difficile strains in Canada and Italy and predictive accuracy of rifampin Etest for rifamycin resistance. J Clin Microbiol 2011;49:4319-21. [PMID: 21998414 DOI: 10.1128/JCM.05100-11] [Cited by in Crossref: 23] [Cited by in F6Publishing: 8] [Article Influence: 2.1] [Reference Citation Analysis]
101 Fumi AL, Trexler K. Rifaximin treatment for symptoms of irritable bowel syndrome. Ann Pharmacother 2008;42:408-12. [PMID: 18303148 DOI: 10.1345/aph.1K345] [Cited by in Crossref: 24] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
102 Mancini A, Campagna F, Amodio P, Tuohy KM. Gut : liver : brain axis: the microbial challenge in the hepatic encephalopathy. Food Funct. 2018;9:1373-1388. [PMID: 29485654 DOI: 10.1039/c7fo01528c] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
103 Gargallo Puyuelo CJ, Sopeña F, Lanas Arbeloa A. Colonic diverticular disease. Treatment and prevention. Gastroenterología y Hepatología 2015;38:590-9. [DOI: 10.1016/j.gastrohep.2015.03.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
104 Lutz P, Nischalke HD, Strassburg CP, Spengler U. Spontaneous bacterial peritonitis: The clinical challenge of a leaky gut and a cirrhotic liver. World J Hepatol 2015; 7(3): 304-314 [PMID: 25848460 DOI: 10.4254/wjh.v7.i3.304] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 4.9] [Reference Citation Analysis]
105 Sciorsci RL, Piccinno M, Rizzo A. Contractile effect of rifaximin on bovine uterus in the presence of steroid hormone antagonists. Theriogenology 2018;110:74-8. [PMID: 29353143 DOI: 10.1016/j.theriogenology.2017.12.049] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
106 Castelli F, Saleri N, Tomasoni LR, Carosi G. Prevention and Treatment of Traveler’s Diarrhea. Digestion 2006;73:109-18. [DOI: 10.1159/000089786] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
107 Ye JF, Ju J. Rifaximin for prevention and treatment of hepatic encephalopathy. Shijie Huaren Xiaohua Zazhi 2015; 23(7): 1090-1096 [DOI: 10.11569/wcjd.v23.i7.1090] [Reference Citation Analysis]
108 Mas A. Hepatic Encephalopathy: From Pathophysiology to Treatment. Digestion 2006;73:86-93. [DOI: 10.1159/000089783] [Cited by in Crossref: 54] [Cited by in F6Publishing: 38] [Article Influence: 3.4] [Reference Citation Analysis]
109 Ramas M, Donday MG, McNicholl AG, Gisbert JP. Efficacy and safety of rifaximin associated with standard triple therapy (omeprazole, clarithromycin and amoxicillin) for H. pylori eradication: A phase IV pilot clinical trial. Gastroenterol Hepatol 2017;40:658-62. [PMID: 28780968 DOI: 10.1016/j.gastrohep.2017.05.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
110 Maccaferri S, Vitali B, Klinder A, Kolida S, Ndagijimana M, Laghi L, Calanni F, Brigidi P, Gibson GR, Costabile A. Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system. J Antimicrob Chemother. 2010;65:2556-2565. [PMID: 20852272 DOI: 10.1093/jac/dkq345] [Cited by in Crossref: 105] [Cited by in F6Publishing: 94] [Article Influence: 8.8] [Reference Citation Analysis]
111 Schoenfeld P, Pimentel M, Chang L, Lembo A, Chey WD, Yu J, Paterson C, Bortey E, Forbes WP. Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials. Aliment Pharmacol Ther. 2014;39:1161-1168. [PMID: 24697851 DOI: 10.1111/apt.12735] [Cited by in Crossref: 57] [Cited by in F6Publishing: 55] [Article Influence: 7.1] [Reference Citation Analysis]
112 Farrell DJ. Rifaximin in the treatment of irritable bowel syndrome: Is there a high risk for development of antimicrobial resistance? J Clin Gastroenterol. 2013;47:205-211. [PMID: 23340064 DOI: 10.1097/mcg.0b013e31827559a3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
113 Shamseya MM, Madkour MA. Rifaximin: A reasonable alternative for norfloxacin in the prevention of spontaneous bacterial peritonitis in patients with HCV-related liver cirrhosis. Alexandria Journal of Medicine 2016;52:219-26. [DOI: 10.1016/j.ajme.2015.09.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
114 Donders GG, Guaschino S, Peters K, Tacchi R, Lauro V; VARIANT 1 Study Group. A multicenter, double-blind, randomized, placebo-controlled study of rifaximin for the treatment of bacterial vaginosis. International Journal of Gynecology & Obstetrics 2013;120:131-6. [DOI: 10.1016/j.ijgo.2012.08.022] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
115 Ponziani FR, Pecere S, Lopetuso L, Scaldaferri F, Cammarota G, Gasbarrini A. Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation. Expert Opin Drug Saf. 2016;15:983-991. [PMID: 27149541 DOI: 10.1080/14740338.2016.1186639] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
116 Yim HJ, Suh SJ, Jung YK, Yim SY, Seo YS, Lee YR, Park SY, Jang JY, Kim YS, Kim HS, Kim BI, Um SH. Daily Norfloxacin vs. Weekly Ciprofloxacin to Prevent Spontaneous Bacterial Peritonitis: A Randomized Controlled Trial. American Journal of Gastroenterology 2018;113:1167-76. [DOI: 10.1038/s41395-018-0168-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
117 Rosette C, Buendia-laysa F, Patkar S, Moro L, Celasco G, Bozzella R, Ajani M, Gerloni M. Anti-inflammatory and immunomodulatory activities of rifamycin SV. International Journal of Antimicrobial Agents 2013;42:182-6. [DOI: 10.1016/j.ijantimicag.2013.04.020] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
118 Betts JW, Phee LM, Wareham DW. Rifaximin combined with polymyxins: A potential regimen for selective decontamination of multidrug-resistant bacteria in the digestive tract? J Glob Antimicrob Resist 2016;4:11-5. [PMID: 27436386 DOI: 10.1016/j.jgar.2015.11.008] [Reference Citation Analysis]
119 Tolefree JA, Garcia AJ, Farrell J, Meadows V, Kennedy L, Hargrove L, Demieville J, Francis N, Mirabel J, Francis H. Alcoholic liver disease and mast cells: What's your gut got to do with it? Liver Research 2019;3:46-54. [DOI: 10.1016/j.livres.2019.02.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
120 Luo W, Guo S, Zhou Y, Zhao J, Wang M, Sang L, Chang B, Wang B. Hepatocellular Carcinoma: How the Gut Microbiota Contributes to Pathogenesis, Diagnosis, and Therapy. Front Microbiol 2022;13:873160. [PMID: 35572649 DOI: 10.3389/fmicb.2022.873160] [Reference Citation Analysis]
121 Liu Y, Chen M. Clostridioides difficile Infection in Liver Cirrhosis: A Concise Review. Can J Gastroenterol Hepatol 2022;2022:4209442. [PMID: 35711246 DOI: 10.1155/2022/4209442] [Reference Citation Analysis]
122 Perencevich M, Burakoff R. Use of antibiotics in the treatment of inflammatory bowel disease: . Inflammatory Bowel Diseases 2006;12:651-64. [DOI: 10.1097/01.mib.0000225330.38119.c7] [Cited by in Crossref: 61] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
123 Baráth B, Jász DK, Horváth T, Baráth B, Maróti G, Strifler G, Varga G, Sándor L, Perényi D, Tallósy S, Donka T, Jávor P, Boros M, Hartmann P. Mitochondrial Side Effects of Surgical Prophylactic Antibiotics Ceftriaxone and Rifaximin Lead to Bowel Mucosal Damage. Int J Mol Sci 2022;23:5064. [PMID: 35563455 DOI: 10.3390/ijms23095064] [Reference Citation Analysis]
124 Kimer N, Krag A, Gluud LL. Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy. Patient Prefer Adherence. 2014;8:331-338. [PMID: 24672227 DOI: 10.2147/PPA.S41565] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
125 Scarpignato C, Di Mario F. Advances in GI Pharmacology and Therapeutics. Dig Dis 2006;24:7-10. [DOI: 10.1159/000092477] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
126 Jacob EM, Borah A, Pillai SC, Kumar DS. Inflammatory Bowel Disease: The Emergence of New Trends in Lifestyle and Nanomedicine as the Modern Tool for Pharmacotherapy. Nanomaterials (Basel) 2020;10:E2460. [PMID: 33316984 DOI: 10.3390/nano10122460] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
127 Biancone L, Annese V, Ardizzone S, Armuzzi A, Calabrese E, Caprioli F, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D’incà R, Frieri G, Fries W, Gionchetti P, Kohn A, Latella G, Milla M, Orlando A, Papi C, Petruzziello C, Riegler G, Rizzello F, Saibeni S, Scribano ML, Vecchi M, Vernia P, Meucci G, Aratari A, Bossa F, Cappello M, Cassinotti A, Chiriatti A, Fiorino G, Formica V, Guidi L, Losco A, Mocciaro F, Onali S, Pastorelli L, Pica R, Principi M, Renna S, Ricci C, Rispo A, Rogai F, Sarmati L, Scaldaferri F, Spina L, Tambasco R, Testa A, Viscido A. Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease 2017;49:338-58. [DOI: 10.1016/j.dld.2017.01.141] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
128 Esposito G, Nobile N, Gigli S, Seguella L, Pesce M, d'Alessandro A, Bruzzese E, Capoccia E, Steardo L, Cuomo R, Sarnelli G. Rifaximin Improves Clostridium difficile Toxin A-Induced Toxicity in Caco-2 Cells by the PXR-Dependent TLR4/MyD88/NF-κB Pathway. Front Pharmacol 2016;7:120. [PMID: 27242527 DOI: 10.3389/fphar.2016.00120] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
129 Berg D, Clemente JC, Colombel JF. Can inflammatory bowel disease be permanently treated with short-term interventions on the microbiome? Expert Rev Gastroenterol Hepatol. 2015;9:781-795. [PMID: 25665875 DOI: 10.1586/17474124.2015.1013031] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
130 Amaldoss MJN, Najar IA, Kumar J, Sharma A. Therapeutic efficacy of rifaximin loaded tamarind gum polysaccharide nanoparticles in TNBS induced IBD model Wistar rats. Rep Pract Oncol Radiother 2021;26:712-29. [PMID: 34760306 DOI: 10.5603/RPOR.a2021.0100] [Reference Citation Analysis]
131 Debbia EA, Maioli E, Roveta S, Marchese A. Effects of rifaximin on bacterial virulence mechanisms at supra- and sub-inhibitory concentrations. J Chemother. 2008;20:186-194. [PMID: 18467244 DOI: 10.1179/joc.2008.20.2.186] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 3.4] [Reference Citation Analysis]
132 Bouza E, Burillo A, Muñoz P. Antimicrobial Therapy of Clostridium difficile-Associated Diarrhea. Medical Clinics of North America 2006;90:1141-63. [DOI: 10.1016/j.mcna.2006.07.011] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
133 Han X, Luo Z, Wang W, Zheng P, Li T, Mei Z, Wang J. Efficacy and Safety of Rifaximin Versus Placebo or Other Active Drugs in Critical ill Patients With Hepatic Encephalopathy. Front Pharmacol 2021;12:696065. [PMID: 34690751 DOI: 10.3389/fphar.2021.696065] [Reference Citation Analysis]
134 Hu H, Lin A, Kong M, Yao X, Yin M, Xia H, Ma J, Liu H. Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives. J Gastroenterol 2020;55:142-58. [PMID: 31845054 DOI: 10.1007/s00535-019-01649-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
135 Latella G, Scarpignato C. Rifaximin in the management of colonic diverticular disease. Expert Rev Gastroenterol Hepatol 2009;3:585-98. [PMID: 19929580 DOI: 10.1586/egh.09.63] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
136 Pimentel M. Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther. 2016;43 Suppl 1:37-49. [PMID: 26618924 DOI: 10.1111/apt.13437] [Cited by in Crossref: 43] [Cited by in F6Publishing: 32] [Article Influence: 7.2] [Reference Citation Analysis]
137 Jodlowski TZ, Lam S, Ashby CR. Emerging therapies for the treatment of Helicobacter pylori infections. Ann Pharmacother. 2008;42:1621-1639. [PMID: 18845620 DOI: 10.1345/aph.1l234] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
138 Kaji K, Takaya H, Saikawa S, Furukawa M, Sato S, Kawaratani H, Kitade M, Moriya K, Namisaki T, Akahane T, Mitoro A, Yoshiji H. Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity. World J Gastroenterol 2017; 23(47): 8355-8366 [PMID: 29307995 DOI: 10.3748/wjg.v23.i47.8355] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 31] [Article Influence: 8.0] [Reference Citation Analysis]
139 Gupta K, Ghuman HS, Handa SV. Review of Rifaximin: Latest Treatment Frontier for Irritable Bowel Syndrome Mechanism of Action and Clinical Profile. Clin Med Insights Gastroenterol 2017;10:1179552217728905. [PMID: 28894393 DOI: 10.1177/1179552217728905] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
140 Scarpignato C, Barbara G, Lanas A, Strate LL. Management of colonic diverticular disease in the third millennium: Highlights from a symposium held during the United European Gastroenterology Week 2017. Therap Adv Gastroenterol 2018;11:1756284818771305. [PMID: 29844795 DOI: 10.1177/1756284818771305] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
141 Staffas A, Burgos da Silva M, van den Brink MR. The intestinal microbiota in allogeneic hematopoietic cell transplant and graft-versus-host disease. Blood 2017;129:927-33. [PMID: 27940475 DOI: 10.1182/blood-2016-09-691394] [Cited by in Crossref: 95] [Cited by in F6Publishing: 97] [Article Influence: 15.8] [Reference Citation Analysis]
142 Miftahussurur M, Waskito LA, Syam AF, Nusi IA, Siregar G, Richardo M, Bakry AF, Rezkitha YAA, Wibawa IDN, Yamaoka Y. Alternative eradication regimens for Helicobacter pylori infection in Indonesian regions with high metronidazole and levofloxacin resistance. Infect Drug Resist. 2019;12:345-358. [PMID: 30774400 DOI: 10.2147/idr.s187063] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]